Boston Scientific reported strong Q2 2024 results with net sales of $4.12 billion, up 14.5% reported and 14.7% organic YoY, exceeding guidance of 10-12%. GAAP net income reached $324 million or $0.22 per share, while adjusted EPS hit $0.62, surpassing guidance of $0.57-0.59.The company saw robust growth across segments, with Cardiovascular up 17.8% and MedSurg rising 9.0%. Regional performance was led by U.S. sales growth of 16.9%, while Emerging Markets grew 14.8%. Key developments included NMPA approval in China for the FARAPULSE PFA System and positive clinical trial results for multiple products.Looking ahead, Boston Scientific raised its full-year 2024 guidance, now expecting net sales growth of 13.5-14.5% reported and 13-14% organic. The company projects full-year GAAP EPS of $1.34-1.38 and adjusted EPS of $2.38-2.42, reflecting continued momentum across its portfolio.

Boston Scientific reported strong Q2 2024 results with net sales of $4.12 billion, up 14.5% reported and 14.7% organic YoY, exceeding guidance of 10-12%. GAAP net income reached $324 million or $0.22 per share, while adjusted EPS hit $0.62, surpassing guidance of $0.57-0.59.The company saw robust growth across segments, with Cardiovascular up 17.8% and MedSurg rising 9.0%. Regional performance was led by U.S. sales growth of 16.9%, while Emerging Markets grew 14.8%. Key developments included NMPA approval in China for the FARAPULSE PFA System and positive clinical trial results for multiple products.Looking ahead, Boston Scientific raised its full-year 2024 guidance, now expecting net sales growth of 13.5-14.5% reported and 13-14% organic. The company projects full-year GAAP EPS of $1.34-1.38 and adjusted EPS of $2.38-2.42, reflecting continued momentum across its portfolio.